Astrazeneca plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.8%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$63.3Bnext fiscal year
FY EPS (est.)
$10.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 9M and Q3 2026 Financial Results | 30 Oct 2026 |
| FY 2026 Full Year and Q4 Results | 10 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Oncology Franchise Revenue Growth Quarterly15.0%Target: Double-digit annual growth to support 2030 targets
Core Gross Margin Quarterly83.0%Target: Stable to slightly higher than 2025 levels
Core R&D Expense as % of Revenue Quarterly23.0%Target: Upper end of the low-20% range
Total Revenue Ambition by 2030 Annually30.7B
Watch Items
- Generic competition impact on Farxiga and BrilintaTrigger: Revenue erosion exceeding 15% in affected marketsAction: Accelerate commercial launches of newer pipeline assets and optimize cost structures.
- Phase III clinical trial readouts (over 20 high-value readouts expected over 18 months)Trigger: Failure to meet primary endpoints in key trials (e.g., recent Ultomiris TA-TMA or Wainua ATTR-CM setbacks)Action: Re-evaluate pipeline prioritization, adjust R&D capital allocation, and engage in regulatory discussions.
- China market performance and volume-based procurement (VBP) pricing pressureTrigger: Double-digit revenue declines in the Chinese marketAction: Diversify regional revenue streams and pivot toward novel oncology therapies less exposed to VBP.
Research as of 2 Sep 2026